Upadacitinib for Refractory Behcet's Syndrome
NCT07080346
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Behcet Syndrome
Interventions
DRUG:
Upadacitinib 15 MG
Sponsor
Liu Tian